Nobel Laureate Roger Kornberg to Chair New ChromaDex Scientific Advisory Board

IRVINE, Calif., July 8, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has appointed Nobel Laureate Roger Kornberg to Chair the Company's newly formed Scientific Advisory Board ("SAB").

The SAB will be comprised of leading researchers, chemists, biochemists and nutritionists, with an emphasis on those having expertise in nicotinamide riboside ("NR"). The SAB's mission is to assist the Company's management team in maximizing the value of the Company's portfolio of patented ingredients by advising on such matters as scientific and research focus, clinical studies, safety and regulatory, commercialization opportunities, and assessing new potential ingredient technologies.

The ChromaDex SAB will be chaired by Kornberg, a Professor at Stanford Medical School, who was awarded the Nobel Prize in Chemistry in 2006 for his research on the molecular basis of eukaryotic transcription. Dr. Kornberg earned his bachelor's degree in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972. He became a postdoctoral fellow at the Laboratory of Molecular Biology in Cambridge, England and then an Assistant Professor of Biological Chemistry at Harvard Medical School in 1976, before moving to his present position as Professor of Structural Biology at Stanford Medical School in 1978. 

Kornberg's father, the late Arthur Kornberg, was a professor of biochemistry at Stanford and was awarded the Nobel Prize for physiology or medicine in 1959. He was among the first to investigate nicotinamide riboside more than 60 years while at the NIH.

Kornberg commented, "Given my father's noteworthy early research of nicotinamide riboside, I have been following ChromaDex's progress on developing its NIAGEN™ nicotinamide riboside as well as the enormous amount of published research that speaks to the health benefits of NR. I look forward to working with the other members of the SAB as well as the Company's management."

Dr. Phillip Frost, Chairman and Chief Executive Officer of Opko Health, Inc. (NYSE: OPK) commented, "As both Opko Health and I are substantial investors in ChromaDex, I am very pleased to see Roger Kornberg become the Chair of ChromaDex's new SAB."         

Frank Jaksch, Jr., founder and CEO of ChromaDex, commented, "We are honored to have Roger Kornberg Chair our recently formed SAB. His outstanding scientific achievements and extensive experience serving on the Boards of other pharma and biotech companies will be valuable as we progress with the development and commercialization of our novel ingredient pipeline, including NR."

About ChromaDex:
ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY®, a caffeine-pTeroPure® co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.

Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Media Inquiries:                         
Beckerman PR
Jerry Schranz
201-465-8020 
[email protected]     

ChromaDex Company Contact:
Laura Kelly, Executive Assistant
949-419-0288
[email protected]

These statements have not been evaluated by the Food and Drug Administration.  These products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

SOURCE ChromaDex Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED